Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
